[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 385
Citations 0
News From the Food and Drug Administration
December 15, 2015

New Form of Tenofovir

JAMA. 2015;314(23):2497. doi:10.1001/jama.2015.16486

A fixed-dose combination tablet containing a new form of the antiretroviral agent tenofovir has gained FDA approval for treating HIV-1 infection in adults and adolescents 12 years or older.

Marketed as Genvoya, the medication contains elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. It’s taken once daily as a complete regimen and is recommended for treatment-naive patients and adults with HIV-1 RNA levels below 50 copies/mL who have taken a stable antiretroviral regimen for at least 6 months without treatment failure (http://1.usa.gov/1RYxl7t). The most common adverse event linked with the drug is nausea.

First Page Preview View Large
First page PDF preview
First page PDF preview
×